{"schema_version":"secwatch.filing_event.v1","accession":"0000926617-23-000077","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2023-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.064022+00:00","generated_at":"2026-06-10T21:34:35.298210+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aspira Women's Health CSO/COO Ryan Phan resigns, transitions to advisor","bullets":["Dr. Ryan Phan resigns as Chief Scientific & Operating Officer effective Sept 15, 2023, becomes advisor Sept 16, 2023.","Consulting agreement pays $20,000/month through Jan 15, 2024; options continue vesting during term.","$50,000 retention bonus forgiven if Phan remains employed through Dec 31, 2023.","Phan to continue as CLIA lab medical director until Jan 15, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000926617-23-000077","json":"https://secwatch.observer/filing/0000926617-23-000077.json","markdown":"https://secwatch.observer/filing/0000926617-23-000077.md","text":"https://secwatch.observer/filing/0000926617-23-000077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000077/0000926617-23-000077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000077/awh-20230907x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:34:35.298210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fd9129c49f","claim":"Ryan Phan resigned as Chief Scientific and Operating Officer at Aspira Women's Health Inc..","evidence_excerpt":"On August 3, 2023, Dr. Ryan Phan, the Chief Scientific and Operating Officer of Aspira Women’s Health Inc., (the “Company), notified the Company that he will resign from these roles with the Company effective September 15, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000077/0000926617-23-000077-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Scientific and Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}